Psoriatic arthritis

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it? Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has provided much-needed reassuring answers.

Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com Listen by Clicking below: 1. EULAR2021 - Day2a 2. EULAR2021 - Day2b

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr.

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Check out this compilation of our EULAR 2021 Day 1 broadcasts below. You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com Listen by Clicking below: Day 1a Day 1b

Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.